Paper39508562
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.
Ishii T and 7 others. Mod Rheumatol, 2025. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study. Papers, record 39508562. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39508562
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Granulomatosis with Polyangiitis | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Japan | |
| Treatment Outcome | |
| Aged | |
| Adult |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42765531 | Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study. | Rheumatology (Oxford) | 2026 | https://conductscience.org/library/papers/42765531 | PubMed |
| 42657158 | Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study. | Front Allergy | 2026 | https://conductscience.org/library/papers/42657158 | PubMed |
| 42552373 | Advances in the treatment of eosinophilic granulomatosis with polyangiitis. | Nat Rev Rheumatol | 2026 | https://conductscience.org/library/papers/42552373 | PubMed |
| 42324522 | Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study. | BMC Pulm Med | 2026 | https://conductscience.org/library/papers/42324522 | PubMed |
| 42279601 | Diagnosis and Treatment Pathway for Eosinophilic Granulomatosis with Polyangiitis in the Allergy Department. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42279601 | PubMed |
| 42100060 | Real-World Effectiveness of MEpolizuMaB in Eosinophilic Granulomatosis with Polyangiitis in Greece: A Protocol for a Multicentre Retrospective Observational Study - The MEMBER Study. | Mediterr J Rheumatol | 2026 | https://conductscience.org/library/papers/42100060 | PubMed |
| 42095000 | Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES. | J Allergy Clin Immunol Glob | 2026 | https://conductscience.org/library/papers/42095000 | PubMed |
| 42051495 | Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42051495 | PubMed |
| 41574554 | Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice. | Allergy | 2026 | https://conductscience.org/library/papers/41574554 | PubMed |
| 40566054 | High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe. | J Clin Med | 2025 | https://conductscience.org/library/papers/40566054 | PubMed |
| 40305320 | Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. | Biomolecules | 2025 | https://conductscience.org/library/papers/40305320 | PubMed |
| 40100113 | Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis. | Sarcoidosis Vasc Diffuse Lung Dis | 2025 | https://conductscience.org/library/papers/40100113 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39508562
GET https://conductscience.org/api/papers/v1/39508562/authors